NCPC(SH:600812) Zheng Quan Zhi Xing·2025-06-05 10:31Core Viewpoint - The company has received approval from the National Medical Products Administration for the injection of Isavuconazonium Sulfate (0.2g), which enhances its product line in the anti-infection sector [1][2]. Group 1: Drug Registration Details - The drug is named Isavuconazonium Sulfate for Injection, with a registration classification as a chemical drug of category 4 [1]. - The drug registration certificate was issued with a validity period of 18 months, and it is classified as a prescription drug [1]. - The company has invested a total of 15.27 million yuan in research and development for this drug [2]. Group 2: Market Situation - Isavuconazonium Sulfate has been approved for sale in over 40 countries globally, with five companies in China holding the registration certificate for the injection form [3]. - The sales revenue for Isavuconazonium Sulfate injection reached 100 million yuan in 2023, with 72.38 million yuan in sales during the first half of 2024 [3]. Group 3: Impact on the Company - The approval of Isavuconazonium Sulfate is expected to further supplement the company's product offerings in the anti-infection field [3].